Acadian Asset Management LLC Cuts Stock Holdings in Achilles Therapeutics plc (NASDAQ:ACHL)

Acadian Asset Management LLC decreased its position in Achilles Therapeutics plc (NASDAQ:ACHL) by 10.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 250,825 shares of the company’s stock after selling 30,104 shares during the quarter. Acadian Asset Management LLC owned approximately 0.61% of Achilles Therapeutics worth $203,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vestal Point Capital LP purchased a new stake in Achilles Therapeutics in the 4th quarter valued at about $96,000. StemPoint Capital LP bought a new position in shares of Achilles Therapeutics during the 1st quarter worth approximately $1,732,000. Finally, Ikarian Capital LLC bought a new position in shares of Achilles Therapeutics in the first quarter valued at approximately $1,804,000. Hedge funds and other institutional investors own 56.38% of the company’s stock.

Achilles Therapeutics Stock Up 10.6 %

ACHL stock opened at $1.04 on Friday. The business has a 50 day moving average of $0.77 and a 200-day moving average of $0.88. Achilles Therapeutics plc has a 12-month low of $0.63 and a 12-month high of $1.76. The firm has a market cap of $42.73 million, a PE ratio of -0.65 and a beta of 1.31.

Achilles Therapeutics (NASDAQ:ACHL) last announced its earnings results on Wednesday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.41). On average, research analysts expect that Achilles Therapeutics plc will post -1.19 earnings per share for the current year.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.